A Phase 1b Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Demcizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Biomarker
- Sponsors OncoMed Pharmaceuticals
- 15 Dec 2011 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 15 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2010 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.